RTP Mobile Logo
Submitted by nenadkesic@gmail.com on Sat, 04/28/2018 - 15:21
LymphomaCLLUpdate118

Interview with Laurie H Sehn, MD, MPH

 

Track 1: Case: A 66-year-old man who presents with nausea, vomiting and weight loss is diagnosed with germinal center B-cell diffuse large B-cell lymphoma (DLBCL)
Track 2: Management of “double-hit” DLBCL
Track 3: CNS International Prognostic Index: A risk model for CNS relapse in patients with DLBCL treated with R-CHOP
Track 4: CNS prophylaxis for patients with DLBCL
Track 5: Assessing the risk of CNS involvement and relapse for patients with primary testicular DLBCL
Track 6: Incidence and risk of bowel perforation in patients with DLBCL and gastrointestinal involvement
Track 7: Case: A 62-year-old man with relapsed/refractory (R/R) Stage IVB activated B-cell-like DLBCL
Track 8: Integration of chimeric antigen receptor (CAR) T-cell therapy into the treatment algorithm for patients with R/R DLBCL
Track 9: Case: A 31-year-old man with Stage IIB classical Hodgkin lymphoma (HL) experiences disease relapse 18 months after receiving ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine)
Track 10: ECHELON-1: Results of a Phase III trial comparing brentuximab vedotin with AVD to ABVD as front-line therapy for Stage III or IV classical HL
Track 11: AETHERA: Efficacy and safety results from a Phase III trial of brentuximab vedotin for patients with HL at high risk of relapse or disease progression after autologous stem cell transplant (ASCT)
Track 12: Activity of immune checkpoint inhibitors in R/R HL
Track 13: Treatment options for elderly patients with newly diagnosed HL
Track 14: Immune-related adverse events associated with checkpoint inhibitors
Track 15: Case: A 72-year-old woman with Grade I/II follicular lymphoma (FL) receives up-front bendamustine/rituximab (BR) followed by maintenance rituximab
Track 16: Primary results of the Phase III GALLIUM study: Obinutuzumab-based induction and maintenance therapy prolongs progression-free survival in comparison to ritixumab-based therapy for previously untreated FL
Track 17: Side effects associated with bendamustine in combination with obinutuzumab or rituximab in the GALLIUM trial
Track 18: StiL NHL7-2008 MAINTAIN: A Phase III trial evaluating 4 versus 2 years of maintenance rituximab after BR for previously untreated FL
Track 19: Perspective on the use of rituximab or obinutuzumab monotherapy for patients with FL

Interview with Andrew D Zelenetz, MD, PhD

Track 1: Management of chronic lymphocytic leukemia (CLL)
Track 2: Approach to R/R CLL after disease progression on ibrutinib
Track 3: Efficacy and tolerability of ibrutinib and venetoclax for CLL
Track 4: Activity of venetoclax with rituximab for R/R CLL
Track 5: Therapeutic options for patients with CLL in the front-line setting
Track 6: Mitigation of the infusion-related reactions associated with obinutuzumab
Track 7: Efficacy and side effects associated with idelalisib for CLL
Track 8: Case: A frail 84-year-old man with del(17p) CLL receives venetoclax and rituximab after disease progression on multiple lines of therapy, including ibrutinib
Track 9: Clinical implications of the GALLIUM trial
Track 10: Perspective on the toxicity associated with bendamustine on the GALLIUM study
Track 11: Selection of therapy for patients with R/R FL
Track 12: Case: A 57-year-old man with FL experiences early relapse on BR and enrolls on a clinical trial of an investigational PI3K delta inhibitor
Track 13: Role of the lenalidomide/rituximab (R2) regimen in FL
Track 14: Case: A 57-year-old woman with ALK-negative anaplastic large cell lymphoma
Track 15: Ongoing Phase II study of high-dose chemotherapy with ASCT followed by maintenance romidepsin for patients with T-cell non-Hodgkin lymphoma
Track 16: Approach to CD30 testing and the use of brentuximab vedotin for patients with T-cell lymphomas
 
FACULTY
 
Laurie H Sehn, MD, MPH
Centre for Lymphoid Cancer
BC Cancer Agency and
University of British Columbia
Vancouver, British Columbia, Canada
 
Andrew D Zelenetz, MD, PhD
Medical Director, Medical Informatics
Department of Medicine
Memorial Sloan
Kettering Cancer Center
New York, New York
 
EDITOR
 
Neil Love, MD
Research To Practice
Miami, Florida